Talk about interesting timing. Just as Fresenius defended canceling its $4.75 billion deal to acquire Akorn over allegations of data integrity fraud, the Food and Drug Administration handed Fresenius a gift, of sorts.
The regulator happened to release over the past few days a pair of inspection reports showing Akorn had several disturbing problems at a manufacturing facility in Switzerland. In particular, a May 2016 inspection found that Akorn had received dozens of complaints over a two-year period of mold contamination — which one customer described as “black gunk” — but the company failed to adequately investigate the problem.
About the Author Reprints
